Package Leaflet: Information for the Patient
Dabigatran Etexilate Normon 75 mg Hard Capsules EFG
Dabigatran Etexilate Normon contains the active substance dabigatran etexilate and belongs to a group of medications called anticoagulants. It works by blocking a substance in the body involved in the formation of blood clots.
Dabigatran etexilate is used in adults to:
Dabigatran etexilate is used in children to:
Consult your doctor before starting to take Dabigatran Etexilate. During treatment with this medication, you may also need to consult your doctor if you experience any symptoms or if you need to undergo surgery.
Tell your doctorif you have or have had any disorder or disease, especially any of the following:
In this case, Dabigatran Etexilate should be temporarily discontinued due to an increased risk of bleeding during and after surgery. It is very important that you take Dabigatran Etexilate before and after surgery exactly at the times indicated by your doctor.
Other medications and Dabigatran Etexilate Normon
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medications. In particular, you must tell your doctor before taking Dabigatran Etexilate if you are taking any of the following medications:
The effects of Dabigatran Etexilate on pregnancy and the fetus are unknown. You should not use Dabigatran Etexilate if you are pregnant unless your doctor tells you it is safe to do so. If you are of childbearing age, you should avoid becoming pregnant during treatment with this medication.
Breastfeeding is not recommended during treatment with Dabigatran Etexilate.
Dabigatran Etexilate has no known effects on the ability to drive and use machines.
Dabigatran Etexilate capsules can be used in adults and children aged 8 years or older who are able to swallow the capsules whole. There are other pharmaceutical forms suitable for children under 8 years of age.
Follow your doctor's instructions for taking this medication exactly. If you are unsure, consult your doctor again.
Take Dabigatran Etexilate Normon as recommended for the following situations:
Prevention of blood clot formation after knee or hip replacement surgery
The recommended dose is 220 mg once daily(administered as 2 capsules of 110 mg).
If your kidney function is reducedby more than half or if you are 75 years of age or older, the recommended dose is 150 mg once daily(administered as 2 capsules of 75 mg).
If you are using medications containing amiodarone, quinidine, or verapamil, the recommended dose is 150 mg once daily(administered as 2 capsules of 75 mg).
If you are using medications containing verapamil and your kidney function is reducedby more than half, you should be indicated a reduced dose of Dabigatran Etexilate of 75 mgbecause your risk of bleeding may increase.
In both types of surgery, treatment should not be started if there is bleeding at the surgical site. If treatment cannot be started until the day after surgery, dosing should be started with 2 capsules once daily.
After knee replacement surgery
Treatment with Dabigatran Etexilate should be started 1-4 hours after surgery, taking a single capsule. Afterward, 2 capsules should be taken once daily for a total of 10 days.
After hip replacement surgery
Treatment with Dabigatran Etexilate should be started 1-4 hours after surgery, taking a single capsule. Afterward, 2 capsules should be taken once daily for a total of 28-35 days.
Treatment of blood clots and prevention of their formation in children
Dabigatran Etexilate should be taken twice daily, one dose in the morning and one dose in the evening, approximately at the same time every day. The administration interval should be as close to 12 hours as possible.
The recommended dose depends on weight and age. Your doctor will determine the correct dose. Your doctor may adjust the dose during treatment. Continue using all other medications unless your doctor tells you to stop using any.
Table 1 shows the single and total daily doses of Dabigatran Etexilate in milligrams (mg). The doses depend on the patient's weight in kilograms (kg) and age in years.
Table 1: Dosing Table for Dabigatran Etexilate
Weight/Age Combinations | Single Dose in mg | Total Daily Dose in mg | |
Weight in kg | Age in years | ||
11 to less than 13 kg | 8 to less than 9 years | 75 | 150 |
13 to less than 16 kg | 8 to less than 11 years | 110 | 220 |
16 to less than 21 kg | 8 to less than 14 years | 110 | 220 |
21 to less than 26 kg | 8 to less than 16 years | 150 | 300 |
26 to less than 31 kg | 8 to less than 18 years | 150 | 300 |
31 to less than 41 kg | 8 to less than 18 years | 185 | 370 |
41 to less than 51 kg | 8 to less than 18 years | 220 | 440 |
51 to less than 61 kg | 8 to less than 18 years | 260 | 520 |
61 to less than 71 kg | 8 to less than 18 years | 300 | 600 |
71 to less than 81 kg | 8 to less than 18 years | 300 | 600 |
81 kg or more | 10 to less than 18 years | 300 | 600 |
Doses requiring combinations of more than one capsule:
300 mg: two 150 mg capsules or four 75 mg capsules
260 mg: one 110 mg capsule plus one 150 mg capsule or one 110 mg capsule plus two 75 mg capsules
220 mg: two 110 mg capsules
185 mg: one 75 mg capsule plus one 110 mg capsule
150 mg: one 150 mg capsule or two 75 mg capsules
Dabigatran Etexilate can be taken with or without food. The capsule should be swallowed whole with a glass of water to ensure release in the stomach. Do not break, chew, or open the capsule to take only its contents, as this may increase the risk of bleeding.
Instructions for opening the blisters
The following images illustrate how to extract the Dabigatran Etexilate capsules from the blister:
Separate an individual blister from the blister strip through the perforated line.
Remove the rear foil and extract the capsule.
Do not change your anticoagulant treatment without specific instructions from your doctor.
Taking too much of this medication increases the risk of bleeding. Contact your doctor immediately if you have taken too many capsules. There are specific treatment options available.
In case of overdose or accidental ingestion, contact your doctor or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
Prevention of blood clot formation after knee or hip replacement surgery
Continue with the remaining daily doses of Dabigatran Etexilate at the same time the next day. Do not take a double dose to make up for missed doses.
Treatment of blood clots and prevention of their formation in children
A missed dose can be taken up to 6 hours before the next dose.
A missed dose should be omitted if the time remaining before the next dose is less than 6 hours.
Do not take a double dose to make up for missed doses.
Take Dabigatran Etexilate exactly as prescribed. Do not stop your treatment with Dabigatran Etexilate without consulting your doctor first, as the risk of developing a blood clot may be greater if you stop treatment too soon.
Contact your doctor if you experience indigestion after taking this medication.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Dabigatran etexilate acts on blood coagulation; therefore, most adverse effects are related to signs such as bruising or bleeding.
Episodes of major or severe bleeding may occur, which are the most serious adverse effects and, regardless of their location, can cause disability, be potentially fatal, or even cause death. In some cases, these bleedings may not be apparent.
If you experience any episode of bleeding that does not stop by itself or if you experience signs of excessive bleeding (exceptional weakness, fatigue, paleness, dizziness, headache, or unexplained swelling), consult your doctor immediately. Your doctor may decide to keep you under close observation or change your medication.
Inform your doctor immediately if you experience a severe allergic reaction that causes difficulty breathing or dizziness.
The possible adverse effects are detailed below, grouped according to their frequency.
Prevention of blood clot formation after knee or hip arthroplasty
Frequent (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Frequency not known (frequency cannot be estimated from available data):
Treatment of blood clots and prevention of new blood clot formation in children
Frequent (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Frequency not known (frequency cannot be estimated from available data):
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is an adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton or blister after "EXP". The expiration date is the last day of the month indicated.
Do not store above 30°C.
Store in the original packaging to protect it from moisture.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE Point in the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Package Contents and Additional Information
The active ingredient is dabigatran. Each hard capsule contains 86.48 mg of dabigatran etexilate (as mesilate) equivalent to 75 mg of dabigatran etexilate.
The capsule shell contains carrageenan, potassium chloride, titanium dioxide (E-171), and hypromellose 2910.
Dabigatran Etexilate Normon 75 mg are hard white or off-white capsules, size 2, containing white or pale yellow pellets.
This medicine is available in packages containing:
10, 30, or 60 hard capsules in single-dose perforated aluminum/OPA-ALU-PVC blisters.
Only some package sizes may be marketed.
Marketing Authorization Holder:
Laboratorios Normon, S.A.
Ronda de Valdecarrizo, 6
Tres Cantos, 28760, Madrid
Manufacturers:
Or
Date of the Last Revision of this Leaflet:12/2023
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
The average price of DABIGATRAN ETEXILATE NORMON 75 mg HARD CAPSULES in October, 2025 is around 11.27 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.